Newest Addition to Company’s Zoom Stroke Solution Provides an Additional Option for Achieving Intracranial Access to Treat Patients for Ischemic Stroke
First Patient Treated with Zoom RDL at Spectrum Health. (Credit: Robina Weermeijer on Unsplash)
Imperative Care, Inc., today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Zoom RDL Radial Access System, the company’s latest innovation in elevating stroke care and the first radial access platform developed specifically for ischemic stroke treatment.
Zoom RDL is the newest addition to Imperative Care’s Zoom Stroke Solution, the company’s ischemic stroke product portfolio that includes the Zoom 88 Large Distal Platform (LDP) for neurovascular access, four purposefully designed vessel-matching Zoom Aspiration Catheters, and the powerful Zoom Pump with Zoom POD for sterile-field clot capture.
The company also announced the successful completion of the first in-human case using Zoom RDL, which was performed by Dr. Justin Singer, M.D., Neurosurgeon at Spectrum Health in Grand Rapids, Michigan. The Zoom RDL was used during treatment of an acute stroke for a patient with a complex anatomy that would have made femoral access challenging. The Zoom RDL provided .088” intracranial access from the radial artery allowing the physician to remove the clot using a Zoom Aspiration Catheter and achieve complete revascularization in less than 20 minutes.
“We are excited to offer a new capability in our patient-first portfolio, empowering physicians with both femoral and radial access options to care for their patients for the best possible outcomes,” said Daniel Davis, President and COO of Imperative Care. “We are committed to providing meaningful solutions that directly address the feedback and needs of physicians through continued innovation of the Zoom Stroke Solution. A radial approach can be beneficial for patients with unfavorable femoral access and can make access site recovery easier for the patient.”
“We are in a new era of stroke thrombectomy, and Zoom RDL is an important part of this evolution that will allow physicians to get closer to the treatment site for quicker, more efficient stroke procedures without compromising device selection,” said Davis.
The introduction of Zoom RDL provides neurointerventionalists with a new option for achieving intracranial access to treat their stroke patients, enabling the best possible outcome based on an individual patient’s anatomy. Zoom RDL features an extended hydrophilic coating and the longest optimized vessel dilator on the market, providing a smooth introduction into the radial artery.
Similar to the company’s FDA-cleared Zoom 88 Large Distal Platform for femoral access, Zoom RDL features a large .088” lumen for compatibility with large-bore aspiration catheters. With an engineered support profile designed to reach the intracranial vasculature, physicians can get higher into the brain and closer to the stroke-causing clot, giving them more control over the mechanical thrombectomy procedure.
Source: Company Press Release